KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

West Pharmaceutical Services (WST) EPS (Basic) (2016 - 2026)

West Pharmaceutical Services has reported EPS (Basic) over the past 18 years, most recently at $1.93 for Q1 2026.

  • Quarterly EPS (Basic) rose 55.65% to $1.93 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.52 through Mar 2026, up 17.13% year-over-year, with the annual reading at $6.83 for FY2025, 1.19% up from the prior year.
  • EPS (Basic) was $1.93 for Q1 2026 at West Pharmaceutical Services, up from $1.83 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $2.53 in Q2 2022 and troughed at $1.24 in Q1 2025.
  • The 5-year median for EPS (Basic) is $1.85 (2023), against an average of $1.84.
  • Biggest five-year swings in EPS (Basic): crashed 31.65% in 2022 and later skyrocketed 55.65% in 2026.
  • Tracing WST's EPS (Basic) over 5 years: stood at $1.38 in 2022, then surged by 34.06% to $1.85 in 2023, then decreased by 3.24% to $1.79 in 2024, then increased by 2.23% to $1.83 in 2025, then grew by 5.46% to $1.93 in 2026.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at $1.93, $1.83, and $1.94 for Q1 2026, Q4 2025, and Q3 2025 respectively.